- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00022529
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
Phase I Study of Intravenous BMS-214662 FTI (NSC# 710086) and Herceptin (NSC# 688097) Weekly in Patients With Advanced Malignancies
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose and recommended phase II dose of BMS-214662 when combined with trastuzumab (Herceptin) in patients with advanced solid tumors.
II. Determine the dose-limiting toxic effects of this regimen in these patients.
SECONDARY OBJECTIVES:
I. Determine the pharmacokinetics of this regimen in these patients. Ii. Determine, in a preliminary manner, the antitumor activity of this regimen in these patients.
OUTLINE: This is a dose-escalation study of BMS-214662.
Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with BMS-214662 and trastuzumab at the recommended phase II dose.
PROJECTED ACCRUAL: A total of 3-28 patients will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19111-2497
- Fox Chase Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically or cytologically confirmed solid tumor that is unresponsive to currently available therapies or for which no known effective therapy exists
- Overexpressing HER-2-neu (2+ or 3+) by immunohistochemistry or fluorescent in situ hybridization
- Clinically or radiologically evaluable disease
No carcinomatous meningitis or untreated/uncontrolled metastatic brain parenchymal disease
- At least 8 weeks since prior therapy for prior brain parenchymal disease and asymptomatic off corticosteroids
- Performance status - ECOG 0-2
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin no greater than 1.8 mg/dL
- ALT and AST no greater than 1.5 times upper limit of normal (ULN)
- Creatinine no greater than 1.5 times ULN
- No uncontrolled or significant cardiovascular disease
- No myocardial infarction within the past 6 months
- No prior clinically significant atrial or ventricular arrhythmias
- No prior second or third degree heart block
- No ischemic heart disease requiring medication
- No congestive heart failure
- Corrected QT interval no greater than 450 milliseconds by electrocardiogram
- Ejection fraction at least lower limit of normal by MUGA scan
- No uncontrolled or significant pulmonary disease
- No active unresolved infection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study
- At least 4 weeks since prior immunotherapy, including trastuzumab (Herceptin), and recovered
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No anthracyclines for at least 22 weeks after completion of study therapy
- No other concurrent chemotherapy
- Concurrent hormone replacement therapy allowed
- No other concurrent hormonal therapy
- At least 4 weeks since prior radiotherapy and recovered
- No prior radiotherapy to more than 25% of the bone marrow-containing skeleton
- No concurrent radiotherapy
- At least 4 weeks since prior investigational agents and recovered
- At least 7 days since prior known substrates of cytochrome P450-3A4 (CYP3A4)
- At least 7 days since prior parenteral antibiotics
- No concurrent substrates of CYP3A4
- No concurrent parenteral antibiotics
- No other concurrent experimental medications
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment (BMS-214662, trastuzumab)
Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlatieve studies
Andere namen:
IV gegeven
Andere namen:
IV gegeven
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
MTD defined as the highest dose level at which =< 1/6 subjects experience a study related dose-limiting toxicity (DLT) as assessed by CTC version 2.0
Tijdsspanne: 28 days
|
28 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Mary Cianfrocca, Fox Chase Cancer Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NCI-2012-02396
- FCCC-01013
- CDR0000068828 (Register-ID: PDQ (Physician Data Query))
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .